Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Name: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
License: Public Domain

National Cancer Institute (NCI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

atypical teratoid/rhabdoid tumor, epithelioid sarcoma, kidney medullary carcinoma, malignant solid neoplasm, poorly differentiated chordoma, recurrent atypical teratoid/rhabdoid tumor

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 141018
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.